All In Biotech

Drug Trial Radar · NCT00066742

Tirapazamine Combined With Chemo and RT in Limited-Stage Small Cell Lung Cancer

A Phase II Study of Tirapazamine (NSC-130181)/Cisplatin/Etoposide and Concurrent Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: May 15, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

72

Actual

Start

Sep 2003

Primary completion

Aug 2009

Study completion Aug 2009

Sponsor

Sponsor type
NIH
First posted
Aug 7, 2003

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial is studying how well giving tirapazamine together with cisplatin, etoposide, and radiation therapy works in treating patients with limited-stage small cell lung cancer. Drugs used in chemotherapy, such as cisplatin and etoposide, work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Tirapazamine may make the tumor cells more sensitive to chemotherapy and radiation therapy. Combining chemotherapy and radiation therapy with tirapazamine may kill more tumor cells.

Conditions

  • Limited Stage Small Cell Lung Cancer

Interventions

  • tirapazamineDrug

    Given IV

  • cisplatinDrug

    Given IV

  • etoposideDrug

    Given IV

  • radiation therapyRadiation

    Undergo radiation therapy

  • laboratory biomarker analysisOther

    Correlative studies

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall SurvivalTime frame: Weekly during protocol treatment, then every 3 months for first year, then every 6 months for up to 3 years after enrollment.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Southwest Oncology Group (SWOG) Research Base

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.